Elizabeth McKenna· @ElizSMcKenna · X·· 2026-04-19评分60
正文 · 原文
Find out more on overcoming BTK inhibitor resistance in CLL by #AACR26 speaker Jennifer Woyach in
@CD_AACR
in the phase I of nemtabrutinib, an orally bioavailable, reversible, ATP-competitive BTK inhibitor designed to inhibit both WT and C481S-mutated BTK
https://
doi.org/10.1158/2159-8
290.CD-23-0670
…
热度 3 · 3 赞 · 0 回复 · 0 转发
会议摘要
982按 药名 nemtabrutinib 对上
Pharmacophore profiling highlights diverging binding modes of nemtabrutinib and ibrutinib across tyrosine kinasesCharly Empereur-mot, Giulio Sartori, Luca Pesce, Filippo Spriano, Chiara Tarantelli, Luciano Cascione, Alberto J. Arribas, Luca Aresu, Davide Rossi, Giovanna L.M. Damia, Massimo Broggini, Daniela Polino, Francesco Bertoni
读摘要原文 →来源：Elizabeth McKenna · x.com